Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- “Character” Tops List of Traits Doctors Require of MRs: MREAC Survey
August 17, 2012
- Higher Dose of Methotrexate Approved: Pfizer
August 17, 2012
- Teijin Pharma Obtains Approval for Bonalon Jelly
August 16, 2012
- Humira Can Be Used for RA Patients without Treatment History: Abbott, Eisai
August 16, 2012
- Eisai’s US Subsidiary Morphotek Opens New Antibody Production Plant
August 16, 2012
- AZ, Pfizer Enter into Agreement for OTC Nexium, Also Eyeing OTC Versions of Other AZ Products
August 16, 2012
- Additional Indication of Pancreatic Neuroendocrine Tumors Approved for Sutent: Pfizer
August 16, 2012
- Symbicort Approved for COPD: Astellas, AZ
August 16, 2012
- Sosei Discontinues Development of Neuropathic Pain Treatment SD118, Transfers Rights to Beijing Tide of China
August 16, 2012
- MRs Ranks 3rd in Number of Average Annual Holidays at 133 Days: Survey
August 15, 2012
- Otsuka HD to Discuss with FDA this Month Delay in Approving Aripiprazole Injection
August 15, 2012
- Differences in Concurrent-Use Indications for DPP-4 Inhibitors to Be Eliminated through Special Clinical Trials
August 15, 2012
- Seikagaku Wins US Patent Suit over Joint Function Improver
August 15, 2012
- Nichi-Iko to Shift to 2-Headquarters System in Oct.
August 15, 2012
- Otsuka HD’s April-June Pharma Sales Up 2.7% Despite Decline in Abilify Sales
August 15, 2012
- RaQualia Representative Director Nagahisa Steps Down, Mr Tani Appointed New Representative Director
August 15, 2012
- Over 20% of Doctors Report Decline in Meetings with MRs Since Revision of Business Entertainment GLs in April: CareNet Survey
August 13, 2012
- Business Strategies of Generics Manufacturers Become Evident Ahead of Upcoming Round of Patent Expiries
August 13, 2012
- Asahi Kasei in Hot Pursuit of Eli Lilly Japan as Competition Heats Up in Market for Bone Formation Agents
August 13, 2012
- Astellas Concludes Marketing Agreement with Nippon Kayaku for Vascular Embolization Material
August 10, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…